SHPH

Shuttle Pharmaceuticals Holdings, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website uttlepharma.com
Employees(FY) 7
ISIN US8256933024

Performance

-21.91%

-24.54%

-55.98%

-71.97%

-75.33%

YTD

-77.56%

Profile

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas, SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers. The company was founded in 2012 and is based in Rockville, Maryland.

Advanced Technical Analysis

Technical Analysis of SHPH 2024-11-20

The stock's Moving Average Score of 10 indicates a strong bearish sentiment, while the Oscillators Score of 56 suggests a neutral stance. Overall, the Technical Score of 33 reinforces the bearish outlook, indicating that the stock may face downward pressure in the near term.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of SHPH

Stock Rank

Recent News & Updates

2024-11-13 04:00
Shuttle Pharma Provides Third Quarter 2024 Corporate Update(Globenewswire)
2024-10-29 09:05
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules(Globenewswire)
2024-10-29 04:05
Shuttle Pharma Pays Off Senior Secured Convertible Note(Globenewswire)
2024-10-28 21:00
Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma(Globenewswire)
2024-10-28 04:05
Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma(Globenewswire)
2024-10-27 21:00
Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024(Globenewswire)
2024-09-15 21:00
Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma(Globenewswire)
2024-09-11 01:00
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing(Accesswire)
2024-09-04 21:00
Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease(Globenewswire)
2024-09-04 04:15
Shuttle Pharma Provides Second Quarter 2024 Corporate Update(Globenewswire)
2024-08-27 21:00
Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement(Globenewswire)
2024-08-26 04:10
Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)(Globenewswire)
2024-08-14 04:10
Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma(Globenewswire)
2024-07-18 21:00
Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE(Globenewswire)
2024-06-17 21:00
Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer(Globenewswire)
2024-05-22 04:15
Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024(Globenewswire)
2024-05-13 21:00
Shuttle Pharma Provides First Quarter 2024 Corporate Update(Globenewswire)
2024-05-13 09:53
SHPH Stock Earnings: Shuttle Pharmaceuticals Reported Results for Q1 2024(Investorplace)
2024-04-28 21:00
Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV(Accesswire)
2024-04-23 04:15
Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024(Globenewswire)
2024-04-02 21:00
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024(Globenewswire)
2024-04-02 19:00
Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now(Globenewswire)
2024-04-01 19:00
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now(Globenewswire)
2024-03-21 21:00
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update(Prnewswire)
2024-03-05 18:00
Presenting on the Emerging Growth Conference 68 Day 2 on March 7 Register Now(Globenewswire)
2024-03-04 20:00
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024(Globenewswire)
2024-03-04 18:00
Presenting on the Emerging Growth Conference 68 Day 1 on March 6 Register Now(Globenewswire)
2024-02-12 19:00
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering(Prnewswire)
2024-01-23 03:30
Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024(Prnewswire)
2024-01-07 20:00
Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma(Prnewswire)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.